A study published in the journal Nature Medicine investigated the clinical utility of whole genome sequencing (WGS) in patients with solid cancers. In a sample of 888 patients who underwent genome-wide sequencing profiling, effective biomarkers enabling targeted therapy were identified in 73% of patients. Targeted therapies based on sequencing results have been associated with clinical benefit, particularly in systemic treatment-naïve patients. The results confirm that WGS can significantly reduce the number of diagnostic errors and lead to a change of diagnosis in some patients. Whole-genome sequencing profiling thus proves to be a valuable tool in the routine diagnosis and treatment of oncology patients. The integration of WGS into the standard clinical care of cancer patients represents a path towards more precision medicine in oncology.